| Literature DB >> 35416574 |
Federica Novelli1, Valentina Pinelli2, Luigi Chiaffi2, Anna Maria Carletti2, Massimiliano Sivori2, Ugo Giannoni3, Fabio Chiesa3, Alessandro Celi4.
Abstract
To evaluate the possible prognostic significance of the development of peripheral consolidations at chest x-ray in COVID-19 pneumonia, we retrospectively studied 92 patients with severe respiratory failure (PaO2/FiO2 ratio < 200 mmHg) that underwent at least two chest x-ray examinations (baseline and within 10 days of admission). Patients were divided in two groups based on the evolution of chest x-ray toward the appearance of peripheral consolidations or toward a greater extension of the lung abnormalities but without peripheral consolidations. Patients who developed lung abnormalities without peripheral consolidations as well as patients who developed peripheral consolidations showed, at follow-up, a significant worsening of the PaO2/FiO2 ratio but a significantly lower mortality and intubation rate was observed in patients with peripheral consolidations at chest x-ray. The progression of chest x-ray toward peripheral consolidations is an independent prognostic factor associated with lower intubation rate and mortality.Entities:
Keywords: COVID-19; Chest x-ray; Consolidation; Prognosis
Mesh:
Year: 2022 PMID: 35416574 PMCID: PMC9005617 DOI: 10.1007/s11547-022-01487-4
Source DB: PubMed Journal: Radiol Med ISSN: 0033-8362 Impact factor: 3.469
Fig. 1Classification of chest x-ray. a Score 1, no peripheral consolidations: reticulations and GGO extended less than 50% of the lung fields, without peripheral consolidations. b Score 2, no peripheral consolidations: reticulations and GGO extended more than 50% of the lung fields, without peripheral consolidations. c Score 1 + peripheral consolidations: reticulations, GGO and consolidations extended less than 50% of the lung fields, presence of peripheral consolidations. d lung abnormalities (reticulations, GGO and consolidations) extended more than 50% of the lung fields, presence of peripheral consolidations. GGO ground-glass opacities
Baseline characteristics of the patients
| Patients characteristics | Baseline |
|---|---|
| Time from symptoms onset (days) | 6.0 [4.0] |
| PaO2/FiO2, mmHg (median [interquartile range]) | 213 [114] |
| White blood cell count (× 103/μL) (median [interquartile range]) | 7.7 [4.5] |
| Neutrophil count (× 103/μL) (median [interquartile range]) | 6.16 [4.47] |
| Neutrophils, % (median [interquartile range]) | 82.6 [9.7] |
| Lymphocyte count (× 103/μL) (median [interquartile range]) | 0.74 [0.58] |
| Lymphocytes, % (median [interquartile range]) | 10.7 [7.0] |
| NLR (median [interquartile range]) | 7.5 [7.6] |
| CRP (mg/dL) (median [interquartile range]) | 7.7 [8.8] |
| PCT (ng/mL) (median [interquartile range]) (only 74 pts) | 0.17 [0.37] |
| PCT > 0.55 ng/mL (number, %) (only 74 pts) | 15 (20.3%) |
CRP C-reactive protein, PCT procalcitonin
*p < 0.05
§p < 0.01
Baseline chest x-ray findings according to stage
| Stage of illness from the onset | Number of patients 92 | Score 1, no PC 65 (70.7%) | Score 1 + PC 11 (12%) | Score 2, no PC 16 (17.3%) |
|---|---|---|---|---|
| Stage 1 (0–4 days) | 22 (23.9%) | 17 (77.3) | 0 | 5 (22.7) |
| Stage 2 (5–8 days) | 50 (54.3%) | 36 (72) | 6 (12) | 8 (16) |
| Stage 3 (9–13 days) | 15 (16.3%) | 8 (53.3) | 5 (33) | 2 (13.3) |
| Stage 4 (≥ 14 days) | 5 (5.4%) | 4 (80) | 0 | 1 (20) |
PC peripheral consolidations
Comparing between patient without and with peripheral consolidations
| Peripheral consolidations | No peripheral consolidations | ||
|---|---|---|---|
| Age | 67.2 ± 10.4 | 72.9 ± 9.7* | |
| Sex M/F, % | 78.3/21.7 | 78.3/21.7 | |
| PaO2/FiO2, mmHg | Baseline | 219.5 [79.0] | 190.0 [118.0] |
| FU | 101.0 [28.0] | 97.5 [30.0] | |
| Δ% | − 50.3 [22.3] | − 47.8 [35.2] | |
| White blood cell count (× 103/μL) | Baseline | 8.15 [4.52] | 7.15 [4.77] |
| FU | 9.55 [4.52] | 10.6 [8.02] | |
| Δ% | 11.3 [70.6] | 56.6 [112.7]* | |
| Neutrophils count (× 103/μL) | Baseline | 6.50 [3.82] | 5.73 [4.92] |
| FU | 8.01 [4.16] | 9.21 [8.25]* | |
| 78.8 [84.5] | 77.8 [115.4]* | ||
| Lymphocyte count (× 103/μL) | Baseline | 0.81 [0.57] | 0.68 [0.54] |
| FU | 0.79 [0.47] | 0.58 [0.47]§ | |
| Δ% | 2.8 [89.3] | − 24.0 [51.5]§ | |
| CRP (mg/dL) | Baseline | 7.4 [5.5] | 10.3 [10.4]* |
| FU | 3.7 [6.7] | 11.3 [11.0]§ | |
| Δ% | − 45.5 [95.6] | 6.8 [137.3]§ | |
| PCT (ng/mL) | Baseline | 0.11 [0.25] | 0.28 [0.58]§ |
| FU | 0.05 [0.12] | 0.23 [0.67]§ | |
| Δ% | − 50.0 [56.2] | 0 [241.7] | |
| PCT > 0.55 ng/mL | Baseline (74 pts) | 6 (14.3%) | 9 (28.1%) |
| FU (86 pts) | 4 (9.1%) | 13 (31%)§ | |
| ETI | 3 (6.5) | 16 (34.8)§ | |
| Death | 6 (13) | 30 (65.2)§ |
CRP C-reactive protein, PCT procalcitonine, FU follow-up, ETI endotracheal intubation
*p < 0.05
§p < 0.01
Multivariate logistic analysis for death/need for endotracheal intubation
| Variable | Odds ratio | 95% CI |
|---|---|---|
| Age | 1.04 | 0.98–1.10 |
| Baseline CRP | 1.02 | 0.93–1.13 |
| Δ% CRP | 1.004 | 1.001–1.009* |
| Δ% Lymphocytes (%) | 0.99 | 0.98–1.01 |
| PCT > 0.55 ng/mL at FU | 3.73 | 0.78–17.80 |
| Peripheral consolidations at CXR | 0.08 | 0.02–0.27§ |
CRP C-reactive protein, PCT procalcitonine, CXR chest x-ray, FU follow-up
*p < 0.05
§p < 0.01